ro7049665
Recombinant proteinexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 10, 2017 (NCT03221179)
Timeline
Indications
Mechanism of action
- Interleukin-2Supplementation
IL2 supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04790916 | Phase 2 | Apr 19, 2021 | Roche |
| NCT03943550 | Phase 1 | May 8, 2019 | Roche |
| NCT03221179 | Phase 1 | Jul 10, 2017 | Roche |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Roche | For profit | 3 | 3 | 2 | 2017 |
1 organizations
Page 1 / 1